



(51) International Patent Classification:

C07C 233/04 (2006.01) A61K 9/51 (2006.01)
C07C 235/06 (2006.01) C08G 65/333 (2006.01)
A61K 47/00 (2006.01)

(21) International Application Number:

PCT/US2024/056109

(22) International Filing Date:

15 November 2024 (15.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/600,250 17 November 2023 (17.11.2023) US

(71) Applicant: ACUITAS THERAPEUTICS, INC.
[CA/CA]; 701 Fifth Avenue, Suite 5400, Seattle, Wash-
ington 98104 (CA).(72) Inventors: ANSELL, Steven M.; 6190 Agronomy Road,
Suite 405, Vancouver, British Columbia V6T 1Z3 (CA).
LIN, Paulo Jia Ching; 6190 Agronomy Road, Suite 405,
Vancouver, British Columbia V6T 1Z3 (CA). TAM, Ying

K.; 6190 Agronomy Road, Suite 405, Vancouver, British
Columbia V6T 1Z3 (CA).

(74) Agent: LIGON, Toby J. et al.; Seed Intellectual Proper-
ty Law Group LLP, Suite 5400, 701 Fifth Avenue, Seattle,
Washington 98104-7064 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: PEGYLATED LIPIDS





FIG. 1



(57) Abstract: Compounds are provided having the following Formula (I): (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein R¹, R², R³, m, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))